A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension
Latest Information Update: 06 Aug 2024
At a glance
- Drugs BOS-580 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Boston Pharmaceuticals
- 01 Aug 2024 Protocol amended to include part D, number of arms increase form 7 to 9, and number of patient increased to 245.
- 01 Aug 2024 Status changed from active, no longer recruiting to recruiting.
- 01 Aug 2024 Planned number of patients changed from 205 to 245.